Buch, Englisch, 268 Seiten, Format (B × H): 160 mm x 240 mm, Gewicht: 464 g
Buch, Englisch, 268 Seiten, Format (B × H): 160 mm x 240 mm, Gewicht: 464 g
Reihe: Medical Science Symposia Series
ISBN: 978-94-010-5196-5
Verlag: Springer Netherlands
Zielgruppe
Research
Fachgebiete
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Endokrinologie
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Kardiologie, Angiologie, Phlebologie
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakologie, Toxikologie
Weitere Infos & Material
1. Individual risk factors for cardiovascular disease.- 2. The lipid hypothesis: is it the only cause of atherosclerosis?.- 3. Life styles and life style related major risk factors: their combined impact in producing epidemic cardiovascular disease, and the potential for prevention.- 4. The role of genetics as a risk factor in cardiovascular disease.- 5. Multiple risk factors in an Italian population in the 1980’s: the Gubbio study.- 6. Cardiovascular risk factors in older individuals.- 7. Retardation and regression of coronary atherosclerosis: fact or fiction?.- 8. Cardiovascular risk factors and intervention in children.- 9. Should (nearly) every postmenopausal woman be treated with estrogen to prevent heart disease?.- 10. Role of insulin resistance in human disease.- 11. The effects of insulin on the cardiovascular system.- 12. Insulin — a risk factor for cardiovascular disease?.- 13. Hypertension and dyslipidemia in high risk families.- 14. Hypertension and aging induce similar changes in molecular, cellular, and connective tissue responses of the arterial wall.- 15. Plasma renin as a risk factor for heart attack and stroke in hypertension.- 16. Cardiovascular risk factor profile of hypertension: therapeutic approaches.- 17. Specific antihypertensive therapy: an achievable goal?.- 18. Effects of blood pressure control on the prevention of cardiovascular complications in older hypertensives.- 19. Calcium channel blockade and coronary vasomotility in hypertension.- 20. Antihypertensive agents and cardiovascular risk.- 21. Hypertension and atherosclerosis: role of calcium antagonists as antiatherogenic agents with an emphasis on clinical trials.- 22. Stepped-care versus individualized antihypertensive treatment in the 1990’s.- 23. Body fat distribution andcardiovascular disease.- 24. Lipoprotein(a) as an athero-antifibrinolytic risk factor.- 25. Aspirin in the secondary prevention of cardiovascular disease.- 26. Interactions of atherogenic lipoproteins with endothelium and blood cells.- 27. Left ventricular mass as a measure of preclinical disease in patients with hypertension.- 28. Increased triglyceride levels and cardiovascular disease.- 29. Whither triglycerides in the cholesterol campaign.- 30. Plasma triglyceride and coronary heart disease.- 31. Role of high density lipoprotein in plasma lipid transport: is cholesterol efflux from cells coupled to lipolysis of triglyceride-rich lipoproteins?.- 32. Non-pharmacological measures to improve HDL-cholesterol and plasma triglyceride levels.- 33. Drugs affecting HDL/triglyceride levels.- 34. Fibrates and reversal of atherogenic particles.- 35. HDL cholesterol: methodological considerations and laboratory performance.